Micvotabart pelidotin, an investigational antibody-drug conjugate, produced a 39% confirmed response rate in a Phase 1 trial of patients with recurrent or metastatic head and neck cancer, according to the study reports. The results point to potential clinical activity in a disease setting where durable options remain limited. The early readout supports continued dose and expansion cohorts to better define response durability and safety. For oncology teams, the signal also adds to a growing set of ADC candidates being tested beyond traditional breast and lung cancer indications, with biomarker strategy likely to shape later-phase trial design.